Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 19 January 2018, 13:35 HKT/SGT
Share:
    

Source: Eisai
Eisai: Oral Antifungal Agent NAILIN Capsules 100mg Approved in Japan

TOKYO, Jan 19, 2018 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. obtained marketing and manufacturing approval for the oral antifungal agent NAILIN Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (fosravuconazole) for the treatment of onychomycosis in Japan on January 19, 2018.

Sato Pharma and Eisai Co., Ltd. are jointly providing information on its proper use.

Fosravuconazole, the active ingredient of NAILIN Capsules 100mg, is a new triazole class oral antifungal component discovered by Eisai. Sato Pharma conducted a Phase III clinical study of the agent in patients with onychomycosis in Japan, and after confirming efficacy and safety of the agent in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017.

Onychomycosis affects 1 in every 10 Japanese people, and there are an estimated approximately 11 million sufferers in Japan. With Sato Pharma now having obtained marketing and manufacturing approval for NAILIN Capsules 100mg, as an oral treatment for onychomycosis, this is the first new treatment for the disease in approximately 20 years.

By providing NAILIN Capsules 100mg as a new option for the treatment of onychomycosis, Sato Pharma and Eisai will strive to fulfil the needs of onychomycosis patients and healthcare professionals.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Jan 19, 2018 13:35 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
May 17, 2018 10:58 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting
Apr 23, 2018 08:43 HKT/SGT
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser
Apr 20, 2018 17:50 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
Apr 19, 2018 11:07 HKT/SGT
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
Apr 13, 2018 13:22 HKT/SGT
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
Apr 2, 2018 12:44 HKT/SGT
Eisai Submits Supplemental New Drug Application to U.S. FDA
Mar 28, 2018 18:33 HKT/SGT
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
Mar 23, 2018 14:41 HKT/SGT
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Mar 23, 2018 13:40 HKT/SGT
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
Mar 14, 2018 11:16 HKT/SGT
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: